They have the partnership with us in the back pocket.
And that partnership has shifted into over-drive with the fast track designation, rapidly expanding cohorts and advancing trials. The results are speaking for themselves
I have no doubt Merck is largely responsible for the fast track designation. There’s lots more to come from this partnership and the news will be good and frequent in biotech terms.
Immutep is like a golf ball on a tee, we are all setup. Get in before we get hit.
my opinions only
CHECKPOINT INHIBITORS - What The?, page-19
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $459.4K | 1.254M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63364 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 133642 | 8 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |